Figure 2. Effects of LINC00152 on gastric cell growth in vitro and in vivo.
(A) Analysis of LINC00152 expression in GC cell lines (MGC-803, BGC-823, SGC-7901, and AGS) compared to the normal gastric epithelium cell line (GES-1) by qPCR (shown as ΔCt). (B) Subcellular localization of LINC00152 was determined using fractionation. After nuclear and cytoplasm separation in BGC-823 and SGC-7901 cells, RNA was extracted from both fractions and LINC00152 expression was measured by qPCR. GAPDH was used as a cytoplasm marker and U6 was used as a nucleus marker. (C) Relative LINC00152 levels in BGC-823 and SGC-7901 cells transfected with pcDNA or pcDNA-LINC00152 were tested by qPCR. (D) Relative LINC00152 levels in BGC-823 and SGC-7901 cells transfected with negative control (si-NC) or LINC00152 siRNAs were tested by qPCR. (E), (F) BGC-823 and SGC-7901 cells were seeded in 96-well plates after transfection with pcDNA-LINC00152, empty vector (pcDNA), LINC00152 siRNA, or negative control, and cell proliferation was assessed daily for 4 days using an MTT assay. (G), (H) Representative colony formation assay in BGC-823 and SGC-7901 cells after transfection with pcDNA-LINC00152, empty vector (pcDNA), LINC00152 siRNA, or negative control. (I) Tumors from mice 16 days after injection of SGC-7901 cells stably transfected with sh-LINC00152 or empty vector. (J) Tumor volumes were calculated after injection every 4 days. (K) Tumors developed from sh-LINC00152-transfected SGC-7901 cells showed lower Ki-67 protein levels than tumors developed from control cells. (L) Tumor weights are represented as mean ± SD. (M) qPCR was performed to detect average LINC00152 expression in xenograft tumors (n = 6). Results are represented as the average ± SD based on 3 independent experiments (*p < 0.05, **p < 0.01).